Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
How does the current valuation (P/E, EV/EBITDA, market cap) compare to peer biotech companies focusing on similar mechanisms?
What are the potential upside and downside risks associated with the upcoming data readouts for the OX2R franchise?
How does the market’s sentiment (60) align with analyst expectations, and is there a potential for a short‑term price move?
27 days ago